Boothbay Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Boothbay Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Sell	15,713 -31,268	-67%	-$2.19M	0.02%	1000
2026 Q1	$3.49M	Buy	+46,981	New	+$3.41M	0.05%	419
2025 Q4	–	Sell	-20,317	Closed	-$1.06M	–	1972
2025 Q3	$1.06M	Buy	+20,317	New	+$991K	0.02%	813
2025 Q2	–	Sell	-26,323	Closed	-$910K	–	1455
2025 Q1	$910K	Sell	26,323 -32,706	-55%	-$1.1M	0.02%	664
2024 Q4	$1.62M	Sell	59,029 -19,122	-24%	-$494K	0.04%	493
2024 Q3	$1.99M	Sell	78,151 -6,845	-8%	-$180K	0.05%	519
2024 Q2	$2.15M	Buy	84,996 +17,355	+26%	+$475K	0.05%	473
2024 Q1	$2.09M	Sell	67,641 -36,724	-35%	-$1.25M	0.04%	491
2023 Q4	$4.21M	Sell	104,365 -100	-0.1%	-$3K	0.11%	254
2023 Q3	$2.75M	Buy	104,465 +15,507	+17%	+$440K	0.07%	397
2023 Q2	$1.53M	Sell	88,958 -33,775	-28%	-$508K	0.03%	658
2023 Q1	$2.03M	Buy	+122,733	New	+$1.43M	0.04%	654
2022 Q1	–	Sell	-107,800	Closed	-$1.8M	–	2270
2021 Q4	$1.8M	Buy	+107,800	New	+$4.56M	0.04%	514

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Boothbay Fund Management's BBIO Position: Q2 2026 in Review

Boothbay Fund Management reduced its BridgeBio Pharma (BBIO) stake by 67% in Q2 2026, selling an estimated $2.19M and leaving 15,713 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #1000.

Boothbay Fund Management first reported a position in BBIO in Q4 2021 and has held it in 13 quarters since. The position peaked at $4.21M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Boothbay Fund Management held 15,713 shares of BridgeBio Pharma worth $1.17M as of Q2 2026.
Boothbay Fund Management sold 31,268 BridgeBio Pharma shares in Q2 2026, an estimated $2.19M.
BridgeBio Pharma made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #1000 holding.
Boothbay Fund Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 13 quarters since.
Boothbay Fund Management's BridgeBio Pharma position peaked at $4.21M in Q4 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.